Neurogene Inc. (NASDAQ:NGNE – Get Free Report) dropped 7.8% on Tuesday after the company announced weaker than expected quarterly earnings. Jennison Associates LLC now owns 533,088 shares of the company’s stock valued at $10,982,000 after buying an additional 138,999 shares during the period. Deutsche Bank AG purchased a new stake in shares of Neurogene during the 2nd quarter valued at approximately $3,354,000. Bank of New York Mellon Corp purchased a new stake in shares of Neurogene during the 2nd quarter valued at approximately $904,000. Neurogene Company Profile(Get Free Report)Neurogene, Inc is a clinical?stage biotechnology company specializing in the development of gene therapies for rare neurological diseases.